Literature DB >> 28665219

Unwinding the Collagen Fibrils: Elucidating the Mechanism of Pirfenidone and Nintedanib in Pulmonary Fibrosis.

Harinath Bahudhanapati1, Daniel J Kass1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28665219      PMCID： PMC5516284          DOI： 10.1165/rcmb.2017-0079ED

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN： 1044-1549            Impact factor:   6.914


× No keyword cloud information.
  13 in total

1.  FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis.

Authors:  Claudia A Staab-Weijnitz; Isis E Fernandez; Larissa Knüppel; Julia Maul; Katharina Heinzelmann; Brenda M Juan-Guardela; Elisabeth Hennen; Gerhard Preissler; Hauke Winter; Claus Neurohr; Rudolf Hatz; Michael Lindner; Jürgen Behr; Naftali Kaminski; Oliver Eickelberg
Journal:  Am J Respir Crit Care Med       Date:  2015-08-15       Impact factor: 21.405

2.  COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No.

Authors:  Kevin K Brown
Journal:  Chest       Date:  2016-06-09       Impact factor: 9.410

Review 3.  Idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Annie Pardo; Moisés Selman
Journal:  Lancet       Date:  2011-06-28       Impact factor: 79.321

4.  Novel Mechanisms for the Antifibrotic Action of Nintedanib.

Authors:  Sunad Rangarajan; Ashish Kurundkar; Deepali Kurundkar; Karen Bernard; Yan Y Sanders; Qiang Ding; Veena B Antony; Jianhua Zhang; Jaroslaw Zmijewski; Victor J Thannickal
Journal:  Am J Respir Cell Mol Biol       Date:  2016-01       Impact factor: 6.914

5.  A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.

Authors:  Larissa Knüppel; Yoshihiro Ishikawa; Michaela Aichler; Katharina Heinzelmann; Rudolf Hatz; Jürgen Behr; Axel Walch; Hans Peter Bächinger; Oliver Eickelberg; Claudia A Staab-Weijnitz
Journal:  Am J Respir Cell Mol Biol       Date:  2017-07       Impact factor: 6.914

6.  Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis.

Authors:  N I Chaudhary; G J Roth; F Hilberg; J Müller-Quernheim; A Prasse; G Zissel; A Schnapp; J E Park
Journal:  Eur Respir J       Date:  2007-02-14       Impact factor: 16.671

7.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis.

Authors:  J S Munger; X Huang; H Kawakatsu; M J Griffiths; S L Dalton; J Wu; J F Pittet; N Kaminski; C Garat; M A Matthay; D B Rifkin; D Sheppard
Journal:  Cell       Date:  1999-02-05       Impact factor: 41.582

8.  Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.

Authors:  Craig E Daniels; Joseph A Lasky; Andrew H Limper; Kathleen Mieras; Edith Gabor; Darrell R Schroeder
Journal:  Am J Respir Crit Care Med       Date:  2009-12-10       Impact factor: 21.405

9.  Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.

Authors:  Ganesh Raghu; Kevin K Brown; Harold R Collard; Vincent Cottin; Kevin F Gibson; Robert J Kaner; David J Lederer; Fernando J Martinez; Paul W Noble; Jin Woo Song; Athol U Wells; Timothy P M Whelan; Wim Wuyts; Emmanuel Moreau; Scott D Patterson; Victoria Smith; Selina Bayly; Jason W Chien; Qi Gong; Jenny J Zhang; Thomas G O'Riordan
Journal:  Lancet Respir Med       Date:  2016-12-07       Impact factor: 30.700

10.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245
View more
  5 in total

Review 1.  New therapeutics based on emerging concepts in pulmonary fibrosis.

Authors:  Vishwaraj Sontake; Prathibha R Gajjala; Rajesh K Kasam; Satish K Madala
Journal:  Expert Opin Ther Targets       Date:  2018-11-28       Impact factor: 6.902

2.  MicroRNA-144-3p targets relaxin/insulin-like family peptide receptor 1 (RXFP1) expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis.

Authors:  Harinath Bahudhanapati; Jiangning Tan; Justin A Dutta; Stephen B Strock; John Sembrat; Diana Àlvarez; Mauricio Rojas; Benedikt Jäger; Antje Prasse; Yingze Zhang; Daniel J Kass
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

Review 3.  Ubiquitination and deubiquitination emerge as players in idiopathic pulmonary fibrosis pathogenesis and treatment.

Authors:  Shuang Li; Jing Zhao; Dong Shang; Daniel J Kass; Yutong Zhao
Journal:  JCI Insight       Date:  2018-05-17

4.  Prolonged Scar-in-a-Jar: an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis.

Authors:  Sarah Rank Rønnow; Rand Qais Dabbagh; Federica Genovese; Carmel B Nanthakumar; Vikki J Barrett; Robert B Good; Sarah Brockbank; Simon Cruwys; Henrik Jessen; Grith Lykke Sorensen; Morten Asser Karsdal; Diana Julie Leeming; Jannie Marie Bülow Sand
Journal:  Respir Res       Date:  2020-05-07

Review 5.  Pathophysiological Roles of Stress-Activated Protein Kinases in Pulmonary Fibrosis.

Authors:  Yoshitoshi Kasuya; Jun-Dal Kim; Masahiko Hatano; Koichiro Tatsumi; Shuichi Matsuda
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.